3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia
6
Neuroblastoma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Melanoma
3
Sarcoma
2
Rhabdomyosarcoma
2
Radiation Injuries
2
Malignant mesenchymal tumor
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Head and Neck Neoplasms
2
Congenital Abnormalities
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
Stomatitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
sargramostim
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled